文献速递慢病防控与筛查免疫规划

NTHi-Mcat疫苗对重度COPD急性加重可能疗效信号的详细分析:一项既往报告的随机2b期试验

A detailed analysis of possible efficacy signals of NTHi-Mcat vaccine against severe COPD exacerbations in a previously reported randomised phase 2b trial.
PubMed 文献 · Vaccine · 2022-09-06

在一项随机、观察者盲法、安慰剂对照2b期试验中,含不可分型流感嗜血杆菌(NTHi)和卡他莫拉菌(Mcat)表面蛋白的研究性疫苗对COPD患者中重度急性加重未显示疫苗效力(VE),但重度急性加重和住院率观察促使进一步评估。次要分析显示,在频繁急性加重者、基线GOLD 4级患者等亚组中,疫苗对重度AECOPD的VE有统计学意义;多变量分析识别出频繁急性加重状态合并吸入糖皮质激素使用与显著VE相关,该亚组VE为74.99%(p<0.001)。结论提示该疫苗对特定COPD患者的重度急性加重可能有潜在效力,需在适当设计的前瞻性临床试验中确认。

要点

  • 在频繁急性加重者中,疫苗对重度AECOPD的VE为52.11%(p=0.015)。
  • 基线GOLD 4级患者中VE为65.43%(p=0.015)。
  • 频繁急性加重合并吸入糖皮质激素使用亚组VE为74.99%(p<0.001)。

核心结论

  • 结果提示NTHi-Mcat疫苗对某些COPD患者的重度急性加重可能有潜在效力,尤其是频繁急性加重且使用吸入糖皮质激素者。
  • 该潜在信号需要在适当设计的前瞻性临床试验中确认。

研究设计与样本

  • 随机、观察者盲法、安慰剂对照2b期试验,纳入稳定期COPD患者(GOLD 2-4级,40-80岁,过去一年至少一次中重度急性加重),接受两剂NTHi-Mcat疫苗或安慰剂加标准治疗。
  • 606例入组,571例纳入效力分析(NTHi-Mcat疫苗组279例,安慰剂组292例)。

主要发现

  • 对重度AECOPD的VE在频繁急性加重者中为52.11%(p=0.015),基线GOLD 4级患者中为65.43%(p=0.015),既往接种肺炎球菌和/或流感疫苗者中为38.24%(p=0.034)。
  • 第二剂后1个月起6-12个月期间,VE为52.49%(p=0.044)。
  • 多变量分析识别出频繁急性加重状态合并基线吸入糖皮质激素使用与显著VE相关,该亚组VE为74.99%(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An investigational vaccine containing non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) surface proteins did not show vaccine efficacy (VE) against combined moderate and severe (moderate/severe) exacerbations in a randomised, observer-blinded, placebo-controlled phase 2b trial of patients with chronic obstructive pulmonary disease (COPD). Nevertheless, observations on rates of severe exacerbations and hospitalisations encouraged further evaluation. METHODS: Patients with stable COPD (moderate to very severe airflow limitation, Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 2-4), 40-80 years and at least one moderate/severe exacerbation in the last year received two doses of NTHi-Mcat vaccine or placebo plus standard care. Secondary analyses were conducted on VE against exacerbations according to severity. Potential predictive factors at baseline for VE against severe exacerbations were explored in post-hoc analyses. RESULTS: Of 606 patients enrolled, 571 were included in the efficacy analysis (279 in NTHi-Mcat vaccine group, 292 in placebo group). VE against severe acute exacerbations of COPD (AECOPD) in various subgroups was 52.11 % (p = 0.015; frequent exacerbators), 65.43 % (p = 0.015; baseline GOLD grade 4), 38.24 % (p = 0.034; previous pneumococcal and/or influenza vaccination). VE was 52.49 % (p = 0.044) for the 6-12 months period after 1 month post-dose 2. Multivariable analysis identified two factors (frequent exacerbator status plus inhaled corticosteroid use at baseline) associated with significant VE against severe AECOPD; in this subpopulation, VE was 74.99 % (p < 0.001). CONCLUSION: Results suggest potential efficacy with the NTHi-Mcat vaccine against severe exacerbations in certain patients with COPD, in particular those who have frequent exacerbations and use inhaled corticosteroids. This potential signal requires confirmation in an appropriately designed prospective clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03281876.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Arora AK, Chinsky K, Keller C, et al. A detailed analysis of possible efficacy signals of NTHi-Mcat vaccine against severe COPD exacerbations in a previously reported randomised phase 2b trial. Vaccine. 2022. PMID: 36068109. doi:10.1016/j.vaccine.2022.08.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。